AIM-HIV PROJECT------------------------Instituto Salud Carlos III
home

The AIDS epidemic

It has been over 30 years since the first recognized cases of HIV infection. With the advent of highly active antiretroviral therapy (HAART) morbidity and mortality due to HIV infection has dramatically decreased. However, the spread of the HIV pandemic continues unabated, particularly in the developing world.

Data from UNAIDS estimate 36.9 million people infected with HIV in 2014, sub-Saharan Africa remains the most severely affected region, with almost 70% of the people living with HIV worldwide (25.8 million). In this region, adolescent girls and young women continue to experience elevated HIV risk and vulnerability. Of the 2.8 million young people aged 15-24 years living with HIV in sub-Saharan Africa in 2014, 63% were female.

Despite the fact that global incidence of HIV infection declined by 35% between 2000 and 2014, the estimated number of people acquiring HIV infection in 2014 was 2 million, the 70% in sub-Saharan Africa (1.4 million). 

AIDS-related deaths have fallen by 42% since the peak in 2004. UNAIDS estimates 1.2 million people died from AIDS-related causes worldwide in 2014. Since the start of the epidemic an estimated 39 million people have died of AIDS-related illnesses.

NEWS 01  

        

Productive HIV-1 infection of human cervical tissue ex vivo is associated with the secretory phase of menstrual cycle. Read more.    

  

NEWS 02

    

10/01/2014. The partners of the project and the Scientific Advisory Board attended the Progress Meeting of the project in Madrid.  

NEWS 03

   

October 7-10, 2013. ISCIII and SEPROX presented an oral communication and a poster in the AIDS Vaccine Conference. Read more.

 

Instituto de Salud Carlos III. 2013. All rights reserved

This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 305938.

Web Map  Legal AdviceAccesibility | Contact

cea unisr seprox biotech IscIII